CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for TNF Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

TNF Pharmaceuticals Inc
1185 Avenue Of The Americas, Suite 249
Phone: (856) 848-8698p:856 848-8698 NEW YORK, NY  10036  United States Ticker: TNFATNFA
Business Summary
TNF Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing two novel therapeutic platforms that treat the causes of disease rather than only addressing the symptoms. Isomyosamine is a drug platform based on a clinical-stage small molecule that regulates the immune system to control TNF-a, which drives chronic inflammation, and other pro-inflammatory cell signaling cytokines. Isomyosamine is being developed to treat diseases and disorders marked by acute or chronic inflammation. Isomyosamine works by regulating the release of numerous pro-inflammatory cytokines. The Company’s second drug platform, Supera-CBD, is being developed to treat chronic pain, addiction and epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and is being developed to address and improve upon the CBD market, which includes both Food and Drug Administration (FDA) approved drugs and CBD products not regulated as drugs.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
3/31/202512/31/2024YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Independent Chairman of the Board Joshua N.Silverman 54 1/1/2021 9/6/2018
President, Director, Chief Medical Officer MitchellGlass 58 6/13/2024 6/13/2024
Interim Chief Financial Officer IanRhodes 52 2/1/2021 2/1/2021
5 additional Officers and Directors records available in full report.

Business Names
Business Name
AKBS
AKER
Akers Acquisition Sub, Inc.
5 additional Business Names available in full report.

General Information
Number of Employees: 2 (As of 12/31/2024)
Outstanding Shares: 14,184,088 (As of 5/13/2025)
Shareholders: 735
Stock Exchange: NASD
Fax Number: (302) 655-5049


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, June 5, 2025